Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/18/2024 | $35.00 → $45.00 | Neutral → Buy | DA Davidson |
10/11/2022 | Peer Perform | Wolfe Research | |
4/11/2022 | $42.00 | Overweight → Neutral | Alembic Global Advisors |
STOCKHOLM, Nov. 6, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ:BIOA) (STOCKHOLM: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the 16th annual Protein & Antibody Engineering Summit (PEGS) conference in Barcelona, Spain. The BT platform uses active Transferrin Receptor (TfR)-mediated transport, enabling up to 70-fold higher penetration of antibodies over the blood brain barrier, without negative effects on hematological safety parameters. During the 16th annual Protein & Antibody Engineering Summit (PEGS) Europe conference, Dr. Per-Ola Freskgård, VP Science & Technology at BioArctic, presented for the first time the design of the proprietary BT pl
Strong Aerospace Aftermarket Drives Top-line Growth Comparisons are year-over-year unless noted otherwise Third Quarter 2024: Sales of $388 million, up 7%; Organic Sales up 4% Operating Margin of 10.8%; Adjusted Operating Margin of 12.3%, up 150 bps Adjusted EBITDA Margin of 19.8%, up 140 bps GAAP EPS of -$0.04; Adjusted EPS of $0.09, down 52% Barnes Group Inc. (NYSE:B), a global provider of highly engineered products, differentiated industrial technologies, and innovative solutions, today reported financial results for the third quarter of 2024. "In the third quarter, despite ongoing production delays from aircraft manufacturers, our Aerospace OEM business generated extraordin
STOCKHOLM, Oct. 24, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials for Alzheimer's Disease Conference (CTAD) held in Madrid, Spain, and virtually from October 29 to November 1. Lars Lannfelt will be one of the keynote speakers at the conference. In addition, BioArctic's partner Eisai present lecanemab data in two oral and one poster presentation at the meeting and three symposia will focus on lecanemab. Data shared will include the importance of continued treatment of Alzheimer's disease, a progressive neurodegenerative disease
4 - BARNES GROUP INC (0000009984) (Issuer)
4 - BARNES GROUP INC (0000009984) (Issuer)
4 - BARNES GROUP INC (0000009984) (Issuer)
SC 13D/A - BARNES GROUP INC (0000009984) (Subject)
SC 13G/A - BARNES GROUP INC (0000009984) (Subject)
SC 13G/A - BARNES GROUP INC (0000009984) (Subject)
4 - BARNES GROUP INC (0000009984) (Issuer)
4 - BARNES GROUP INC (0000009984) (Issuer)
4 - BARNES GROUP INC (0000009984) (Issuer)
DA Davidson upgraded Barnes Group from Neutral to Buy and set a new price target of $45.00 from $35.00 previously
Wolfe Research initiated coverage of Barnes Group with a rating of Peer Perform
Alembic Global Advisors downgraded Barnes Group from Overweight to Neutral and set a new price target of $42.00
Barnes Shareholders to Receive $47.50 Per Share in Cash Barnes Group Inc. (NYSE:B) ("Barnes" or "the Company"), a global provider of highly engineered products, differentiated industrial technologies and innovative solutions, announced today that it has entered into a definitive agreement to be acquired by funds managed by affiliates of Apollo Global Management, Inc. (NYSE:APO) ("Apollo") (the "Apollo Funds") in an all-cash transaction that values Barnes at an enterprise value of approximately $3.6 billion. The agreement provides that Barnes shareholders will receive $47.50 per share in cash. The per share purchase price represents a premium of approximately 22% over Barnes' undisturbed c
Barnes Group Inc. (NYSE:B) today announced it will release third quarter 2024 financial results on Friday, October 25, 2024, before the market opens. Barnes will also host a conference call which will begin at 8:30 a.m. (ET) on that day to discuss the results and the Company's outlook. The public may access the conference through a live audio webcast available on the Investor Relations section of the Barnes website at www.onebarnes.com. The conference is also available by direct dial at (888) 510-2379 in the U.S. or (646) 960-0691 outside of the U.S.; Conference ID 1137078. Supplemental materials will be posted to the Investor Relations section of the Company's website prior to the confere
The Board of Directors of Barnes Group Inc. (NYSE:B) has declared a quarterly cash dividend of sixteen cents ($0.16) per share. The dividend will be payable September 10, 2024, to shareholders of record at the close of business on August 22, 2024. Barnes and its predecessor companies have paid a cash dividend to stockholders on a continuous basis since 1934. About Barnes Barnes Group Inc. (NYSE:B) leverages world-class manufacturing capabilities and market-leading engineering to develop advanced processes, automation solutions, and applied technologies for industries ranging from aerospace and medical & personal care to mobility and packaging. With a celebrated legacy of pioneering ex
PREM14A - BARNES GROUP INC (0000009984) (Filer)
10-Q - BARNES GROUP INC (0000009984) (Filer)
8-K - BARNES GROUP INC (0000009984) (Filer)
Announces Planned Retirements of Chairman Thomas O. Barnes and Lead Independent Director Mylle H. Mangum, and appointment of Richard Hipple as Chair Elect Appoints Irenic Capital Management Co-Founder Adam Katz to the Board Enters into Cooperation Agreement with Irenic Capital Management Barnes Group Inc. (NYSE:B), a global provider of highly engineered products, differentiated industrial technologies, and innovative solutions, today announced the planned retirements of Chairman Thomas O. Barnes and Lead Independent Director Mylle H. Mangum, consistent with the Company's corporate governance retirement policy, effective at the Company's Annual Meeting of Stockholders in May 2024. Mr.
Barnes Group Inc. (NYSE:B), a global provider of highly engineered products, differentiated industrial technologies, and innovative solutions, today announced the appointment of Neal J. Keating to the Company's Board of Directors, effective February 9, 2023. Mr. Keating has also been appointed to the Company's Corporate Governance Committee. "We are pleased to welcome Neal to our Board of Directors," said Thomas O. Barnes, Chairman of the Board, Barnes Group Inc. "Neal brings extensive public company and board experience, and importantly he expands the Board's capabilities through his significant leadership experience in the aerospace industry, which aligns well with our growing Barnes Aer
Board Names Medical Technology CEO and Barnes Director as Company's New Leader After Dempsey's Nearly 10 Years as Barnes' CEO Barnes Group Inc. (NYSE:B), a global provider of highly engineered products, differentiated industrial technologies, and innovative solutions, today announced that its Board of Directors has appointed Thomas J. Hook, (59), as President and Chief Executive Officer, effective as of July 14, 2022. Patrick J. Dempsey, who began a leave of absence on March 8, 2022 from his position as President & CEO of the Company to address health matters affecting an immediate family member, will transition to the newly created role of Executive Vice Chairman of the Company until his
About 14% of the S&P 500 companies have reported their June quarter earnings and the blended earnings growth rate for the companies constituting the broader index remains healthy. The coming week will see the official start of the tech reporting season, which could potentially decide the fate of the market, which has seen a steep pullback in the recent week. The Week That Was: The tech earnings season had a modest start last week with the earnings report from chip-equipment maker ASML Holding N.V. (NASDAQ:ASML). The stock slumped about 16%, dragged by its weak third-quarter outlook and geopolitical concerns surrounding the China chip ban. Netflix, Inc.’s (NASDAQ:NFLX) guidance disappointe
- Bloomberg
Oppenheimer analyst Christopher Glynn maintains Barnes Gr (NYSE:B) with a Outperform and raises the price target from $43 to $48.